Floatz logo

Sulperazon

Cholangitis, Secondary Biliary

Tongji HospitalPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cholangitis, Secondary Biliary cohort.

Asset / SponsorPhaseRating
TEIKOPLANIN
Tongji Hospital
Phase 4BB
Meropenem
Tongji Hospital
Phase 4B

Same molecule, other indications

Sulperazon is also rated in:

biliary atresiaDormant
D
Indicative ·
30 / 100
View asset →
cholangitisDormant
D
Indicative ·
30 / 100
View asset →
Anti-Bacterial AgentsDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →